MBIO insiders were on both sides of the trade this year. Buys came to roughly $237 (one buyer), sales to $241 (two sellers).
Biggest single buyer: Jin David, Director, with roughly $237.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 23 investment managers listed MBIO in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Herskowitz Neil | Director | Sell | 247 | $0.96 | $237 | SEC |
| Dec 30, 2025 | Chill Adam J. | Director | Sell | 4 | $0.95 | $4 | SEC |
| Dec 30, 2025 | Jin David | Director | Buy | 247 | $0.96 | $237 | SEC |
| Apr 3, 2023 | Litchman Manuel MD | Director | Buy | 5,000 | $0.74 | $4K | SEC |
| Apr 3, 2023 | Litchman Manuel MD | Director | Buy | 5,000 | $0.52 | $3K | SEC |
| Apr 3, 2023 | ROSENWALD LINDSAY A MD | Director | Buy | 4,094 | $0.74 | $3K | SEC |
| Apr 3, 2023 | ROSENWALD LINDSAY A MD | Director | Buy | 5,000 | $0.52 | $3K | SEC |
In the last 12 months Mustang Bio, Inc. insiders made open-market purchases worth about $237 and sales worth about $241. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MBIO was filed on 2025-12-30.
23 investment managers reported holding MBIO in SEC Form 13F filings for Q2 2026.
No congressional trades in MBIO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).